Elevance Health stock carries a USD 27 adjusted EPS outlook

Elevance Health stock stood at USD 398.56 on the NYSE on September 23, 2026, 8.64 percent below its 52-week high of USD 436.24. On September 10, the company reaffirmed a 2026 adjusted earnings outlook of at least USD 27 per diluted share, according to Investing.com. The combination gives the stock a clear earnings anchor even as the market price remains below its yearly peak.

USD 27 EPS outlook stays intact

The guidance includes a reported adjusted EPS floor of USD 20.10 before the company separates unfavorable one-time items. The underlying adjusted figure of at least USD 27 stands against a consensus estimate of USD 26.91, a difference of USD 0.09 per share, according to Investing.com.

Management also kept its 2026 benefit expense ratio target at 90.2 percent, with a 0.5 percentage point tolerance. For investors, that ratio is the operating variable to watch because medical-cost pressure can change the earnings conversion of premium revenue.

Second-quarter figures beat estimates

Elevance reported second-quarter 2026 adjusted EPS of USD 7.45, compared with USD 6.21 consensus, a USD 1.24 beat. Revenue reached USD 49.83 billion against USD 48.88 billion expected, putting reported revenue USD 0.95 billion above consensus, according to MarketBeat. Revenue was also up 0.8 percent from the prior-year quarter, while prior-year EPS was USD 8.84.

The figures show the central tension in the stock. The latest quarter exceeded expectations, but the year-over-year EPS comparison remains lower, making the USD 27 outlook and medical-cost ratio more important than revenue growth alone.

Stock remains below yearly high

Elevance Health stock was down USD 3.87, or 0.96 percent, at USD 398.56 on the NYSE on September 23, 2026. Its 52-week range was USD 274.84 to USD 436.24, while market capitalization stood at USD 86,435,424,222 on the same quote date.